Ikarian Capital, LLC Altimmune, Inc. Call Options Transaction History

Ikarian Capital, LLC

4 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2023 May 15, 2023	BUY	$4.19 - $16.83 $1.35 Million - $5.41 Million	321,200 Added 55.63%	898,600 $3.79 Million
Q4 2022 Feb 14, 2023	SELL	$8.74 - $16.45 $2.32 Million - $4.36 Million	-265,200 Reduced 31.47%	577,400 $9.5 Million
Q3 2022 Nov 14, 2022	BUY	$10.67 - $22.41 $5.75 Million - $12.1 Million	539,000 Added 177.54%	842,600 $10.8 Million
Q2 2022 Aug 12, 2022	BUY	$3.94 - $11.77 $1.2 Million - $3.57 Million	303,600 New	303,600 $3.55 Million

186

39.3M

913K

743K

Ticker ALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,025,300
Market Cap $349M
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.